Tumor battlefield within inflamed, excluded or desert immune phenotypes: the mechanisms and strategies

The tumor microenvironment demonstrates great immunophenotypic heterogeneity, which has been leveraged in traditional immune-hot/cold tumor categorization based on the abundance of intra-tumoral immune cells. By incorporating the spatial immune contexture, the tumor immunophenotype was further elaborated into immune-inflamed, immune-excluded, and immune-desert. However, the mechanisms underlying these different immune phenotypes are yet to be comprehensively elucidated. In this review, we discuss how tumor cells and the tumor microenvironment interact collectively to shape the immune landscape from the perspectives of tumor cells, immune cells, the extracellular matrix, and cancer metabolism, and we summarize potential therapeutic options according to distinct immunophenotypes for personalized precision medicine.

• Publication year

  2024

• Venue

  Experimental Hematology & Oncology

• Publication date

  2024-08-06

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1186/s40164-024-00543-1PMID 39107856PMCID 11301948
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• A glutamine tug-of-war between cancer and immune cells: recent advances in unraveling the ongoing battle

  2024cited by this paper
• Current and future immunotherapeutic approaches in pancreatic cancer treatment

  2024cited by this paper
• Feedback loop between hypoxia and energy metabolic reprogramming aggravates the radioresistance of cancer cells

  2024cited by this paper
• Analysis of 3D pathology samples using weakly supervised AI.

  2024cited by this paper
• TET2-mediated tumor cGAS triggers endothelial STING activation to regulate vasculature remodeling and anti-tumor immunity in liver cancer

  2024cited by this paper
• Tertiary lymphoid structures and B cells determine clinically relevant T cell phenotypes in ovarian cancer

  2024cited by this paper
• Myeloid-derived suppressor cells in cancer: therapeutic targets to overcome tumor immune evasion

  2024cited by this paper
• An oncolytic virus delivering tumor-irrelevant bystander T cell epitopes induces anti-tumor immunity and potentiates cancer immunotherapy

  2024cited by this paper
• Macrophage-coated tumor cluster aggravates hepatoma invasion and immunotherapy resistance via generating local immune deprivation

  2024influential reference
• Neoantigens: promising targets for cancer therapy

  2023cited by this paper
• Macrophages at the interface of the co-evolving cancer ecosystem.

  2023cited by this paper
• Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications

  2023cited by this paper
• Platinum-based chemotherapy attenuates the effector response of CD8 T cells to concomitant PD-1 blockade.

  2023cited by this paper
• The tumor-derived cytokine Chi3l1 induces neutrophil extracellular traps that promote T cell exclusion in triple-negative breast cancer.

  2023cited by this paper
• Irradiation plus myeloid-derived suppressor cell-targeted therapy for overcoming treatment resistance in immunologically cold urothelial carcinoma

  2023cited by this paper
• T cell egress via lymphatic vessels is tuned by antigen encounter and limits tumor control

  2023cited by this paper
• Targeting tumor vasculature to improve antitumor activity of T cells armed ex vivo with T cell engaging bispecific antibody

  2023cited by this paper
• Spatially Resolved Transcriptomics Technology Facilitates Cancer Research

  2023cited by this paper
• Mature tertiary lymphoid structures are key niches of tumour-specific immune responses in pancreatic ductal adenocarcinomas

  2023cited by this paper
• Machine learning-based glycolysis-associated molecular classification reveals differences in prognosis, TME, and immunotherapy for colorectal cancer patients

  2023cited by this paper
• Angiopoietin-2–Dependent Spatial Vascular Destabilization Promotes T-cell Exclusion and Limits Immunotherapy in Melanoma

  2023influential reference
• ID1 expressing macrophages support cancer cell stemness and limit CD8+ T cell infiltration in colorectal cancer

  2023cited by this paper
• Identification of a tumour immune barrier in the HCC microenvironment that determines the efficacy of immunotherapy.

  2023cited by this paper
• Barriers to immune cell infiltration in tumors

  2023cited by this paper
• Extracellular matrix remodeling in tumor progression and immune escape: from mechanisms to treatments

  2023cited by this paper
• An integrated bioinformatic analysis of bulk and single-cell sequencing clarifies immune microenvironment and metabolic profiles of lung adenocarcinoma to predict immunotherapy efficacy

  2023cited by this paper
• MCT4-dependent lactate secretion suppresses antitumor immunity in LKB1-deficient lung adenocarcinoma.

  2023cited by this paper
• Comprehensive Immune Profiling Unveils a Subset of Leiomyosarcoma with “Hot” Tumor Immune Microenvironment

  2023cited by this paper
• Breast cancer heterogeneity and its implication in personalized precision therapy

  2023cited by this paper
• Decoding the tumor microenvironment with spatial technologies

  2023cited by this paper
• SLC38A2 and glutamine signalling in cDC1s dictate anti-tumour immunity

  2023cited by this paper
• Artificial intelligence for digital and computational pathology

  2023cited by this paper
• Transcriptome-based identification of tumor-reactive and bystander CD8+ T cell receptor clonotypes in human pancreatic cancer

  2023cited by this paper
• Combined PD-L1/TGFβ blockade allows expansion and differentiation of stem cell-like CD8 T cells in immune excluded tumors

  2023cited by this paper
• Cancer immune exclusion: breaking the barricade for a successful immunotherapy

  2023cited by this paper
• Arginine reprograms metabolism in liver cancer via RBM39

  2023cited by this paper
• Hypoxic niches attract and sequester tumor-associated macrophages and cytotoxic T cells and reprogram them for immunosuppression.

  2023cited by this paper
• Effects of altered glycolysis levels on CD8+ T cell activation and function

  2023cited by this paper
• NSUN2 is a glucose sensor suppressing cGAS/STING to maintain tumorigenesis and immunotherapy resistance.

  2023cited by this paper
• ScRNA-seq revealed an immunosuppression state and tumor microenvironment heterogeneity related to lymph node metastasis in prostate cancer

  2023cited by this paper
• Desmoplastic stroma restricts T cell extravasation and mediates immune exclusion and immunosuppression in solid tumors

  2023influential reference
• Dendritic cells as shepherds of T cell immunity in cancer.

  2023cited by this paper
• Immunotherapy for Metastatic Triple Negative Breast Cancer: Current Paradigm and Future Approaches

  2023cited by this paper
• Organoids as an Enabler of Precision Immuno-Oncology

  2023cited by this paper
• Single‐cell transcriptome sequencing of B‐cell heterogeneity and tertiary lymphoid structure predicts breast cancer prognosis and neoadjuvant therapy efficacy

  2023cited by this paper
• POSTN Secretion by Extracellular Matrix Cancer-Associated Fibroblasts (eCAFs) Correlates with Poor ICB Response via Macrophage Chemotaxis Activation of Akt Signaling Pathway in Gastric Cancer

  2023cited by this paper
• Down-regulation of stimulator of interferon genes (STING) expression and CD8+ T-cell infiltration depending on HER2 heterogeneity in HER2-positive gastric cancer

  2023cited by this paper
• Multiomics technologies for comprehensive tumor microenvironment analysis in triple-negative breast cancer under neoadjuvant chemotherapy

  2023cited by this paper
• Tertiary lymphoid structures in desmoplastic melanoma have increased lymphocyte density, lymphocyte proliferation, and immune cross talk with tumor when compared to non-desmoplastic melanomas

  2023cited by this paper
• Long-term outcomes following CAR T cell therapy: what we know so far

  2023cited by this paper
• Time to hit pause on mitochondria-targeting cancer therapies

  2023cited by this paper
• Interplay between Solid Tumors and Tumor Microenvironment

  2022cited by this paper
• Turning cold tumors hot: from molecular mechanisms to clinical applications.

  2022cited by this paper
• In vivo labeling reveals continuous trafficking of TCF-1+ T cells between tumor and lymphoid tissue

  2022cited by this paper
• Delivery of CXCL9/10/11 plasmid DNAs promotes the tumor-infiltration of T cells and synergizes with PD1 antibody for treating lung cancer

  2022cited by this paper
• Exploration of Different Hypoxia Patterns and Construction of a Hypoxia-Related Gene Prognostic Index in Colorectal Cancer

  2022cited by this paper
• Immunosuppressive cells in cancer: mechanisms and potential therapeutic targets

  2022cited by this paper
• Anti-TGF-β/PD-L1 bispecific antibody promotes T cell infiltration and exhibits enhanced antitumor activity in triple-negative breast cancer

  2022cited by this paper
• Heterogeneity of the tumor immune microenvironment and its clinical relevance

  2022cited by this paper
• Tumor-associated high endothelial venules mediate lymphocyte entry into tumors and predict response to PD-1 plus CTLA-4 combination immunotherapy.

  2022cited by this paper
• The hallmarks of cancer metabolism: Still emerging.

  2022cited by this paper
• Combination of oral STING agonist MSA-2 and anti-TGF-β/PD-L1 bispecific antibody YM101: a novel immune cocktail therapy for non-inflamed tumors

  2022cited by this paper
• Senescent stromal cells: roles in the tumor microenvironment.

  2022cited by this paper
• Lactic acid promotes PD-1 expression in regulatory T cells in highly glycolytic tumor microenvironments.

  2022cited by this paper
• Metabolic communication in the tumour–immune microenvironment

  2022cited by this paper
• Periostin‐ and podoplanin‐positive cancer‐associated fibroblast subtypes cooperate to shape the inflamed tumor microenvironment in aggressive pancreatic adenocarcinoma

  2022cited by this paper
• Interrupting the nitrosative stress fuels tumor-specific cytotoxic T lymphocytes in pancreatic cancer

  2022cited by this paper
• Peritumoral tertiary lymphoid structure and tumor stroma percentage predict the prognosis of patients with non-metastatic colorectal cancer

  2022cited by this paper
• Carcinomas assemble a filamentous CXCL12–keratin-19 coating that suppresses T cell–mediated immune attack

  2022cited by this paper
• TGF-β signaling in the tumor metabolic microenvironment and targeted therapies

  2022cited by this paper
• Cell death-induced immunogenicity enhances chemoimmunotherapeutic response by converting immune-excluded into T-cell inflamed bladder tumors

  2022cited by this paper
• Warburg effect in colorectal cancer: the emerging roles in tumor microenvironment and therapeutic implications

  2022cited by this paper
• Metabolic profiles of regulatory T cells and their adaptations to the tumor microenvironment: implications for antitumor immunity

  2022cited by this paper
• Neoadjuvant durvalumab improves survival in early triple-negative breast cancer independent of pathological complete response.

  2022cited by this paper
• Spatial heterogeneity of infiltrating T cells in high-grade serous ovarian cancer revealed by multi-omics analysis

  2022cited by this paper
• Immune checkpoint modulators in cancer immunotherapy: recent advances and emerging concepts

  2022cited by this paper
• Progranulin mediates immune evasion of pancreatic ductal adenocarcinoma through regulation of MHCI expression

  2022cited by this paper
• Targeting Glutamine Metabolism to Enhance Immunoprevention of EGFR‐Driven Lung Cancer

  2022cited by this paper
• PGE2-EP2/EP4 signaling elicits immunosuppression by driving the mregDC-Treg axis in inflammatory tumor microenvironment.

  2022cited by this paper
• Comprehensive Analysis of Senescence Characteristics Defines a Novel Prognostic Signature to Guide Personalized Treatment for Clear Cell Renal Cell Carcinoma

  2022cited by this paper
• Higher proportions of CD39+ tumor-resident cytotoxic T cells predict recurrence-free survival in patients with stage III melanoma treated with adjuvant immunotherapy

  2022cited by this paper
• Targeting inflamed and non-inflamed melanomas: biological background and clinical challenges.

  2022cited by this paper
• Single-cell and spatial analysis reveal interaction of FAP+ fibroblasts and SPP1+ macrophages in colorectal cancer

  2022cited by this paper
• Spatial positioning and matrix programs of cancer-associated fibroblasts promote T cell exclusion in human lung tumors

  2022cited by this paper
• Single-cell atlases link macrophages and CD8+ T-cell subpopulations to disease progression and immunotherapy response in urothelial carcinoma

  2022cited by this paper
• Mapping the Immune Landscape in Metastatic Melanoma Reveals Localized Cell–Cell Interactions That Predict Immunotherapy Response

  2022cited by this paper
• Hallmarks of Cancer: New Dimensions.

  2022cited by this paper
• Emerging strategies in targeting tumor-resident myeloid cells for cancer immunotherapy

  2022cited by this paper
• Tertiary lymphoid structures generate and propagate anti-tumor antibody-producing plasma cells in renal cell cancer.

  2022cited by this paper
• Myeloid-derived suppressor cells: an emerging target for anticancer immunotherapy

  2022cited by this paper
• Myeloid-derived suppressor cells as immunosuppressive regulators and therapeutic targets in cancer

  2021cited by this paper
• Spatiotemporal co-dependency between macrophages and exhausted CD8+ T cells in cancer

  2021cited by this paper
• Integrated analysis reveals prognostic value of HLA-I LOH in triple-negative breast cancer

  2021cited by this paper
• Targeted elimination of myeloid-derived suppressor cells via regulation of the STAT pathway alleviates tumor immunosuppression in neuroblastoma.

  2021cited by this paper
• Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives

  2021cited by this paper
• Combine and conquer: manganese synergizing anti-TGF-β/PD-L1 bispecific antibody YM101 to overcome immunotherapy resistance in non-inflamed cancers

  2021cited by this paper
• WNT as a Driver and Dependency in Cancer.

  2021cited by this paper
• Metabolic modulation of tumours with engineered bacteria for immunotherapy

  2021cited by this paper
• Spatial immunophenotypes predict response to anti-PD1 treatment and capture distinct paths of T cell evasion in triple negative breast cancer

  2021influential reference
• Amateur antigen‐presenting cells in the tumor microenvironment

  2021cited by this paper

• Critical Insight into the Relationship and Dynamic Complexity of Pyroptosis and Inflammation in Cancer Microenvironment: Potential Multifaceted Intervention Points in Tumor Immunotherapy

  2026cites this paper
• Pathological features of residual head and neck cancer after near-infrared photoimmunotherapy: implications of an unfavorable tumor immune microenvironment.

  2026cites this paper
• The ZNF737-CXCL10 axis drives immune exclusion and resistance to anti-PD-1 therapy in bladder cancer.

  2026cites this paper
• From Immunobiology to Clinical Application: Tumor-Infiltrating Lymphocytes in Melanoma

  2026cites this paper
• SF3A2: a promising therapeutic target and predictive biomarker for immunotherapy in colorectal cancer

  2026cites this paper
• Differences in T-cell counts and neighborhood patterns in human colorectal adenomas and sessile serrated lesions

  2026cites this paper
• Cross‐Cancer Perspectives on CD40 Agonist Therapy: Modulating the Tumor Immune Microenvironment

  2026cites this paper
• RAS/MEK/PI3K pathway inhibition augments response to CD40 agonism by targeting CD11b+ Bregs thereby overcoming melanoma PD1-resistance

  2026cites this paper
• Terminally exhausted CD8+ T cells in solid tumors: biology, biomarker potential and translational tools for precision oncology

  2026cites this paper
• Steroid Phenotype Stratification Reveals Distinct HLA Expression Signatures in Adrenocortical Carcinoma

  2026cites this paper
• Nanomedicines Reshape the Tumor Microenvironment: Multidimensional Strategies from Modulating “Barriers” to Metabolic Intervention

  2026cites this paper
• The tumor microenvironment: adding pieces to the puzzle

  2026cites this paper
• Efficacy and safety of PD-1/PD-L1 inhibitors plus chemotherapy in breast cancer: a systematic review and meta-analysis with focus on triple-negative subtype and immune-related adverse events

  2026cites this paper
• POSTN⁺ cancer-associated fibroblast–CCL3⁺ macrophage crosstalk defines the immune-excluded tumor microenvironment in clear cell renal cell carcinoma

  2026cites this paper
• A supramolecular peptide reprograms PD-L1+ tumor-associated macrophages to enhance antitumor immunity in lung adenocarcinoma.

  2026cites this paper
• Reprogramming the melanoma tumor immune microenvironment via combinatorial signal 2/3 gene delivery

  2026cites this paper
• In vivo engineering of CAR-T cells: delivery strategies and clinical translation

  2026cites this paper
• Platelets in the tumor microenvironment: potential mediators of immune exclusion and resistance to immune checkpoint inhibitor therapy

  2026cites this paper
• Immunotherapeutic advances in pediatric neuroblastoma: Overcoming resistance through biomarker-guided combinations.

  2026cites this paper
• The dysregulation of the immune microenvironment during endometrial intraepithelial neoplasia serves as a marker of endometrial carcinogenesis

  2026cites this paper
• Obesity- and tumor-derived signals drive cancer-associated state transitions in breast mesenchymal stromal/stem cells reprogrammed by IL1RA or JAK inhibition

  2026cites this paper
• Digital spatial profiling reveals additive effects of triple therapy on tumor microenvironment: anti-PD-L1, anti-VEGF, and PARP inhibition in mouse models

  2026cites this paper
• Hot-yet-suppressed under PD-1 blockade: an RMP-NRF2-PD-L1 axis associated with a reduced proportional response in hepatocellular carcinoma.

  2026cites this paper
• Methods and applications of patient-derived organoid models for immune microenvironment and immunotherapy research in multiple cancer types

  2026cites this paper
• Radiomic features of CECT and SUVmax of dual-tracer PET/CT reveal PD-L1 spatial heterogeneity in PDAC.

  2026cites this paper
• Reprogramming the tumor immune microenvironment in cervical cancer: synergy between radiotherapy and immunotherapy.

  2026cites this paper
• The application prospects of amino acid deprivation for cancer therapy.

  2026cites this paper
• Neoadjuvant chemotherapy-induced immune remodeling in ovarian cancer: implications for TIL dynamics and combination immunotherapy.

  2026cites this paper
• Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer.

  2026cites this paper
• Tertiary lymphoid structures correlate with reduced recurrence risk and enhanced antitumor immunity in esophageal squamous cell carcinoma with pathologic non-complete response to neoadjuvant chemoimmunotherapy

  2026cites this paper
• Cancer-Immunity Cycle-Based Smart Nucleic Acid Nanodrugs for Potentiated Immunotherapy

  2026cites this paper
• Research Progress on the Interaction between Renal Cancer and the Tumor Microenvironment and Its Potential Therapeutic Strategies

  2026cites this paper
• Targeted therapies in lung cancer: personalizing treatment across the age spectrum

  2026cites this paper
• Millimeter-scale, high-density three-dimensional constructs recapitulate hot and cold tumor microenvironment.

  2026cites this paper
• The neuro-immune axis in cancer: from mechanisms to therapeutic opportunities

  2025cites this paper
• In Situ Vaccination by Tumor Ablation: Principles and Prospects for Systemic Antitumor Immunity

  2025cites this paper
• Decoding the immune microenvironment in osteosarcoma: new insights into checkpoints, vaccines, and CAR-T cells

  2025cites this paper
• Genome Editing Against HPV-Driven Cancers: From Bench to Clinic

  2025cites this paper
• From chronic inflammation to immune escape: mapping the tumor microenvironment evolution in renal cell carcinoma

  2025cites this paper
• Immunotherapy Rechallenge of Advanced NSCLC with Acquired EGFR T790M Mutation after EGFR-TKI Therapy: A Case Report

  2025cites this paper
• Applications of traditional Chinese medicine in cancer immunotherapy via gut microbiota modulation: Current status, mechanisms, challenges and perspectives.

  2025cites this paper
• Tertiary lymphoid structures in cancer: spatiotemporal heterogeneity, immune orchestration, and translational opportunities

  2025cites this paper
• High INHBB Expression Shapes an Immunosuppressive Tumor Microenvironment and Predicts Poor Prognosis in Colorectal Carcinoma.

  2025cites this paper
• Sirtuins and tumor immunity: mechanistic insights, immunotherapy prospects, and therapeutic horizons

  2025cites this paper
• Development and validation of a CAF-related signature for prognosis and therapy response in colorectal cancer: new insights on HSPB1

  2025cites this paper
• Interpretable multimodal radiopathomics model predicting pathological complete response to neoadjuvant chemoimmunotherapy in esophageal squamous cell carcinoma

  2025cites this paper
• A Spatiotemporal Model of CXCL10 as a Master Regulator of Immune Evasion and Metastasis in Osteosarcoma

  2025cites this paper
• Artificial Intelligence in Histopathological Analysis for Predicting Immunotherapy Response in Cutaneous Melanoma

  2025cites this paper
• Immune Watchdogs: Tissue-Resident Lymphocytes as Key Players in Cancer Defense.

  2025cites this paper
• Overcoming immunotherapy resistance in gastric cancer: insights into mechanisms and emerging strategies

  2025cites this paper
• Optogenetically Activatable MLKL as a Standalone Functional Module for Necroptosis and Therapeutic Applications in Antitumoral Immunity

  2025cites this paper
• Anti-TGF-β/PD-L1 bispecific antibody synergizes with radiotherapy to enhance antitumor immunity and mitigate radiation-induced pulmonary fibrosis

  2025cites this paper
• Integrating spatial and single-cell transcriptomes reveals the role of COL1A2(+) MMP1(+/-) cancer-associated fibroblasts in ER-positive breast cancer

  2025influential citation
• Current advancement of immune function paradox of tumour-infiltrating cells and their immunotherapeutic targets: a mini-review

  2025cites this paper
• Post-translational modifications of immune checkpoints: unlocking new potentials in cancer immunotherapy

  2025cites this paper
• Tumor Microenvironment Dynamics of Triple-Negative Breast Cancer Under Radiation Therapy

  2025cites this paper
• Expanding the Therapeutic Reach of Chimeric Antigen Receptor T-Cells and Bispecific T-Cell Engagers Across Solid Tumors.

  2025cites this paper
• Mapping immunotherapy potential: spatial transcriptomics in the unraveling of tumor-immune microenvironments in head and neck squamous cell carcinoma

  2025cites this paper
• Reciprocal Modulation of Tumour and Immune Cell Motility: Uncovering Dynamic Interplays and Therapeutic Approaches

  2025influential citation
• Neutrophil/lymphocyte ratio: a potential biomarker in patients with head and neck squamous cell carcinoma treated with immune checkpoint inhibitors

  2025cites this paper
• Deciphering the molecular heterogeneity of soft tissue sarcoma by integrating multiomics and single cell sequence.

  2025cites this paper
• Integrating multi-omics data with artificial intelligence to decipher the role of tumor-infiltrating lymphocytes in tumor immunotherapy.

  2025cites this paper
• Myeloid‐Derived Suppressor Cells in Cancer: Mechanistic Insights and Targeted Therapeutic Innovations

  2025cites this paper
• Prediction of metastatic potential of heterogeneous pancreatic ductal adenocarcinoma through gradient-based algorithms.

  2025cites this paper
• Targeted degradation of sICOSL reverses cytotoxic T cells dysfunction

  2025cites this paper
• The role of RAB GTPases in predicting prognosis and therapy response in pancreatic cancer

  2025cites this paper
• Decoding the metabolic dialogue in the tumor microenvironment: from immune suppression to precision cancer therapies

  2025cites this paper
• Prognostic impact of immune phenotype in oral squamous cell carcinoma.

  2025cites this paper
• Single-cell and spatial transcriptomics profile the interaction of SPP1+ macrophages and FAP+ fibroblasts in non-small cell lung cancer

  2025cites this paper
• In situ–formed immunotherapeutic hydrogel containing sphingosine-1-phosphate for enhanced lung cancer immunotherapy

  2025cites this paper
• In-depth insight into tumor-infiltrating stromal cells linked to tertiary lymphoid structures and their prospective function in cancer immunotherapy

  2025cites this paper
• CD47 antibody-armed oncolytic adenovirus promotes chimeric antigen receptor macrophage phagocytosis and antitumor immunity

  2025cites this paper
• Integrative Single‐Cell and Machine Learning Analysis Reveals Immune Microenvironment Remodelling in Lymph Node Metastasis of Lung Adenocarcinoma

  2025cites this paper
• Unraveling Resistance in Lung Cancer Immunotherapy: Clinical Milestones, Mechanistic Insights, and Future Strategies

  2025cites this paper
• FGL1-mediated lymph node metastasis in stage T1 non-small cell lung cancer: therapeutic targeting

  2025cites this paper
• Transforming cancer immunotherapy: integration of distinct immune-based approaches as redefined dual immunotherapy with potential third-sensitizer

  2025cites this paper
• Novel tumor-infiltrating lymphocytes therapy in solid tumors: latest updates from 2025 ASCO annual meeting

  2025cites this paper
• Infiltration characteristics and regulatory mechanisms of CD8+ T lymphocytes in solid tumors: spatial distribution, biological functions, and interactions with the immune microenvironment

  2025cites this paper
• TGF-β–driven T-cell exclusion in ovarian cancer: single-cell and spatial transcriptomic views of immune low-response states

  2025cites this paper
• Telomere–metabolism–immunity axis in sarcoma: Immune evasion mechanisms and therapeutic strategies

  2025cites this paper
• Regulatory network and spatial modeling reveal cooperative mechanisms of resistance and immune escape in ER+ breast cancer

  2025cites this paper
• PD-L1+ Lymphocytes Are Associated with CD4+, Foxp3+CD4+, IL17+CD4+ T Cells and Subtypes of Macrophages in Resected Early-Stage Non-Small Cell Lung Cancer

  2024cites this paper
• Association of PD-1 + Treg/PD-1 + CD8 ratio and tertiary lymphoid structures with prognosis and response in advanced gastric cancer patients receiving preoperative treatment

  2024cites this paper
• Harnessing m1A modification: a new frontier in cancer immunotherapy

  2024cites this paper
• Spatial immunogenomic patterns associated with lymph node metastasis in lung adenocarcinoma

  2024cites this paper